A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2017-09-24Actual
Enrollment · participants138Actual
Source updated2025-10-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.